Condition: Non-Hodgkin Lymphoma · Advanced Solid Tumor · Sponsor: Axter Therapeutics (Beijing) Co., Ltd
This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.
This description comes directly from the study's public registry record.
Wilson Wang · +86 10 65120010 · wilson.wang@axtertx.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| Hunan Cancer Hosptial | Changsha, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Sun Yat-Sen University Cancer Center | Guangzhou, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06484985